Moderna and Recursion Use AI to Accelerate Drug Development, But Recursion's Widening Losses Raise Concerns

Moderna uses AI to speed up drug development and mRNA sequencing. It recently partnered with IBM to leverage quantum computing and AI for faster discoveries.

Moderna has over 40 programs in development and plans to launch 15 new products in the next 5 years, so its growth prospects extend beyond just AI.

Recursion Pharmaceuticals uses its AI platform for faster drug discovery, but doesn't expect product revenue anytime soon.

Recursion has an unproven AI platform and widening losses, making it a risky AI stock pick right now.

Nvidia recently invested $50 million in Recursion, but the stock has already given back most of its gains, showing investor skepticism.